Next Article in Journal
Heterologous Booster Dose with CORBEVAX following Primary Vaccination with COVISHIELD Enhances Protection against SARS-CoV-2
Previous Article in Journal
Neutralizing Antibody Responses Elicited by Inactivated Whole Virus and Genetic Vaccines against Dominant SARS-CoV-2 Variants during the Four Epidemic Peaks of COVID-19 in Colombia
Previous Article in Special Issue
Effectiveness of the BNT162b2 mRNA Vaccine Compared with Hybrid Immunity in Populations Prioritized and Non-Prioritized for COVID-19 Vaccination in 2021–2022: A Naturalistic Case-Control Study in Sweden
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 10
Issue 12
10.3390/vaccines10122145
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments

by
Xirui Zhang
1,†,
Hao Yuan
1,†,
Zipeng Yang
1,2,†,
Xiaoyu Hu
1,
Yasser S. Mahmmod
3,4,
Xiaojing Zhu
1,
Cuiping Zhao
5,
Jingbo Zhai
6,
Xiu-Xiang Zhang
1,
Shengjun Luo
2,
Xiao-Hu Wang
2,
Mengzhou Xue
7,*,
Chunfu Zheng
2,8,* and
Zi-Guo Yuan
1,*
1
Guangdong Provincial Key Laboratory of Zoonosis Prevention and Control, College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China
2
Institute of Animal Health, Guangdong Academy of Agricultural Sciences, Key Laboratory of Livestock Disease Prevention of Guangdong Province, Scientific Observation and Experiment Station of Veterinary Drugs and Diagnostic Techniques of Guangdong Province, Ministry of Agriculture and Rural Affairs, Guangzhou 510640, China
3
Infectious Diseases, Department of Animal Medicine, Faculty of Veterinary Medicine, Zagazig University, Zagazig 44511, Egypt
4
Veterinary Sciences Division, Al Ain Men’s College, Higher Colleges of Technology, Abu Dhabi 17155, United Arab Emirates
5
The 80th Army Hospital of the Chinese people’s Liberation Army, Weifang 261021, China
6
Key Laboratory of Zoonose Prevention and Control at Universities of Inner Mongolia Autonomous Region, Medical College, Inner Mongolia Minzu University, Tongliao 028000, China
7
Department of Cerebrovascular Diseases, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014, China
8
Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, AB T2N 4N1, Canada
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Vaccines 2022, 10(12), 2145; https://doi.org/10.3390/vaccines10122145
Submission received: 8 November 2022 / Revised: 7 December 2022 / Accepted: 8 December 2022 / Published: 14 December 2022
(This article belongs to the Special Issue Current Status and Future Perspective of Vaccines against SARS-CoV-2)
Review Reports Versions Notes

Abstract

Since the SARS-CoV-2 outbreak, pharmaceutical companies and researchers worldwide have worked hard to develop vaccines and drugs to end the SARS-CoV-2 pandemic. The potential pathogen responsible for Coronavirus Disease 2019 (COVID-19), SARS-CoV-2, belongs to a novel lineage of beta coronaviruses in the subgenus arbovirus. Antiviral drugs, convalescent plasma, monoclonal antibodies, and vaccines are effective treatments for SARS-CoV-2 and are beneficial in preventing infection. Numerous studies have already been conducted using the genome sequence of SARS-CoV-2 in comparison with that of other SARS-like viruses, and numerous treatments/prevention measures are currently undergoing or have already undergone clinical trials. We summarize these studies in depth in the hopes of highlighting some key details that will help us to better understand the viral origin, epidemiology, and treatments of the virus.
Keywords: SARS-CoV-2; COVID-19; evolution; vaccines; drug; treatments SARS-CoV-2; COVID-19; evolution; vaccines; drug; treatments

Share and Cite

MDPI and ACS Style

Zhang, X.; Yuan, H.; Yang, Z.; Hu, X.; Mahmmod, Y.S.; Zhu, X.; Zhao, C.; Zhai, J.; Zhang, X.-X.; Luo, S.; et al. SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments. Vaccines 2022, 10, 2145. https://doi.org/10.3390/vaccines10122145

AMA Style

Zhang X, Yuan H, Yang Z, Hu X, Mahmmod YS, Zhu X, Zhao C, Zhai J, Zhang X-X, Luo S, et al. SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments. Vaccines. 2022; 10(12):2145. https://doi.org/10.3390/vaccines10122145

Chicago/Turabian Style

Zhang, Xirui, Hao Yuan, Zipeng Yang, Xiaoyu Hu, Yasser S. Mahmmod, Xiaojing Zhu, Cuiping Zhao, Jingbo Zhai, Xiu-Xiang Zhang, Shengjun Luo, and et al. 2022. "SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments" Vaccines 10, no. 12: 2145. https://doi.org/10.3390/vaccines10122145

APA Style

Zhang, X., Yuan, H., Yang, Z., Hu, X., Mahmmod, Y. S., Zhu, X., Zhao, C., Zhai, J., Zhang, X.-X., Luo, S., Wang, X.-H., Xue, M., Zheng, C., & Yuan, Z.-G. (2022). SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments. Vaccines, 10(12), 2145. https://doi.org/10.3390/vaccines10122145

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop